PPIs and Nutrient Absorption: B12, Iron, Magnesium, and Calcium
Proton pump inhibitors — omeprazole, lansoprazole, pantoprazole, esomeprazole, and others — are among the most prescribed drug classes in the world. They work by irreversibly blocking the proton pumps in gastric parietal cells, substantially reducing stomach acid. For people with GERD, peptic ulcers, or Barrett's esophagus, this is the point. But gastric acid is not just a problem to manage. Several essential nutrients depend on it — directly or indirectly — to be absorbed from food and supplements. Long-term PPI use, particularly daily use for a year or more, has documented effects on vitamin B12, iron, magnesium, and calcium absorption, through four distinct mechanisms.
Vitamin B12: the protein unbinding problem
Dietary vitamin B12 arrives in food tightly bound to proteins. Before it can be absorbed, gastric acid must denature those proteins to release B12 in free form. Once free, B12 binds to intrinsic factor — secreted by the same parietal cells that produce acid — and travels to the ileum for absorption. PPIs suppress both acid secretion and parietal cell function, impairing each step: the acid-dependent protein release and the intrinsic factor-dependent ileal uptake.
The NIH ODS Vitamin B12 fact sheet identifies chronic PPI use as a recognized cause of B12 malabsorption. An important nuance: crystalline B12 in supplements (tablets, sublingual lozenges) is already unbound from protein and does not require the acid-dependent release step. High-dose crystalline B12 supplements are substantially less affected by PPI therapy than dietary B12 from meat and dairy. People on long-term PPIs who are concerned about B12 status are better served by a supplement than by increasing dietary sources alone.
Iron: acid-dependent conversion to the absorbable form
Most dietary iron and many iron supplements contain iron in the ferric state (Fe³⁺). The intestinal DMT1 transporter absorbs iron only in the ferrous form (Fe²⁺). That conversion — Fe³⁺ to Fe²⁺ — requires an acidic environment. PPIs raise stomach pH, impairing this conversion and reducing non-heme iron absorption. The NIH ODS Iron fact sheet identifies this as a clinically relevant interaction. Epidemiological studies have found associations between long-term PPI use and iron deficiency.
The effect is most pronounced with ferric iron forms. Ferrous iron supplements (ferrous sulfate, ferrous gluconate) are already in the Fe²⁺ state and do not require conversion, though some evidence suggests they may still be modestly affected by reduced gastric solubility under acid-suppressed conditions. Heme iron, from red meat and poultry, uses a completely separate absorption pathway and is not affected by PPIs. Taking iron supplements with vitamin C may partially compensate — vitamin C reduces Fe³⁺ to Fe²⁺ through a direct chemical mechanism that does not depend on stomach pH.
Magnesium: a separate mechanism that oral supplements cannot reliably fix
PPI-associated hypomagnesemia is mechanistically distinct from the B12 and iron interactions. It does not involve acid suppression impairing absorption — it involves PPIs impairing active magnesium transport in the colon through a pathway that is still not fully characterized. The FDA issued a safety communication in 2011 requiring all PPI labeling to include a warning about this interaction, noting it typically occurs with long-term use (usually more than one year) and may be severe enough to cause muscle cramps, irregular heartbeat, and seizures.
What makes this interaction particularly notable is that oral magnesium supplementation does not reliably correct PPI-induced hypomagnesemia in many affected individuals. Some people require intravenous magnesium or discontinuation of the PPI to restore normal magnesium levels. Simply adding a magnesium supplement while continuing long-term PPI therapy may not be sufficient.
Calcium: form matters more than it does for iron
Calcium carbonate — the most common and inexpensive calcium supplement form — requires gastric acid to dissolve and ionize before it can be absorbed. In an acid-suppressed environment, calcium carbonate absorption is impaired. The NIH ODS Calcium fact sheet notes that calcium citrate does not require gastric acid and is the preferred form for people on acid-reducing medications or with achlorhydria. Epidemiological studies have found associations between long-term PPI use and increased fracture risk, consistent with impaired long-term calcium absorption.
People on long-term PPIs who take calcium supplements should use calcium citrate rather than calcium carbonate to minimize this interaction. This is a straightforward switch that substantially reduces the acid-dependency of the supplement.
How to think about this in practice
None of these interactions are reasons to stop a PPI if a clinician has recommended it. For someone with Barrett's esophagus or a history of GI bleeding, the protection a PPI provides is clinically significant. But for people on long-term daily PPIs, these interactions are worth knowing and worth discussing with a prescriber at regular intervals — particularly for B12 status in older adults (who are already at risk for deficiency), iron status in premenopausal women and anyone with iron-deficiency anemia, and magnesium status in anyone experiencing unexplained muscle symptoms or cardiac arrhythmias.